STRS Ohio’s ImmunityBio IBRX Stock Holding History

STRS Ohio’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,600	Closed	-$39K	–	2040
2022 Q2	$39K	Sell	10,600 -4,900	-32%	-$19.7K	﹤0.01%	1894
2022 Q1	$86K	Hold	15,500	–	–	﹤0.01%	1871
2021 Q4	$94K	Hold	15,500	–	–	﹤0.01%	1908
2021 Q3	$150K	Hold	15,500	–	–	﹤0.01%	1859
2021 Q2	$221K	Buy	15,500 +7,900	+104%	+$131K	﹤0.01%	1787
2021 Q1	$180K	Buy	+7,600	New	+$197K	﹤0.01%	1814
2020 Q4	–	Sell	-7,500	Closed	-$52K	–	2211
2020 Q3	$52K	Buy	7,500 +1,300	+21%	+$13K	﹤0.01%	1963
2020 Q2	$76K	Buy	+6,200	New	+$35K	﹤0.01%	1843
2015 Q4	–	Sell	-2,200	Closed	-$25K	–	1934
2015 Q3	$25K	Buy	+2,200	New	+$48K	﹤0.01%	1806

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

STRS Ohio's IBRX Position: Q3 2022 in Review

STRS Ohio sold out of ImmunityBio (IBRX) in Q3 2022, closing a stake of 10,600 shares — an estimated $39K sold.

STRS Ohio first reported a position in IBRX in Q3 2015 and held it in 9 quarters. The position peaked at $221K in Q2 2021. 126 funds tracked by Wall St. Rank hold IBRX as of Q3 2022.

STRS Ohio reported no remaining ImmunityBio position as of Q3 2022 after selling out during the quarter.
STRS Ohio sold 10,600 ImmunityBio shares in Q3 2022, an estimated $39K.
STRS Ohio first reported a position in ImmunityBio in Q3 2015 and held it in 9 quarters.
STRS Ohio's ImmunityBio position peaked at $221K in Q2 2021.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2022.

Based on STRS Ohio's 13F filing for Q3 2022, filed 27 Oct 2022.